Cardiff Oncology

Cardiff Oncology was founded in 1999, with a mission to address cancer by developing onvansertib, a first-in-class third-generation Polo-like kinase 1 (PLK1) inhibitor, to treat cancers with the greatest unmet medical need, overcome therapy resistance, improve responsiveness, and increase overall survival.